Pfizer, Novartis ink respiratory deal

Pfizer has inked a deal to market Novartis's chronic obstructive pulmonary disease drug Seebri Breezhaler (glycopyrronium bromide) and the Ultimo Breezhaler (indacaterol/glycopyrronium bromide) in Great Britain. Pfizer said in a statement that the country's National Health Service estimates around three million residents have COPD, one of the most common respiratory diseases.

The category has gotten a significant amount of attention of late, such as GlaxoSmithKline's efforts to shore up its Ellipta franchise and AstraZeneca's recent Almirall purchase to beef up its respiratory portfolio.


Next Article in Channel